Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 77.66 USD | +1.38% | +3.02% | -9.54% | |
| Nov. 30 | Wall Street: ideal end to the session, perfect November | CF |
| Nov. 29 | Amazon: 'Black Friday' and 're:Invent' support the stock | CF |
ETFs positioned on Gilead Sciences, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.99% | 323 M€ | -7.64% | - | |
| 8.71% | 396 M€ | -3.81% | ||
| 8.14% | 15 M€ | -6.69% | ||
| 8.10% | 0 M€ | -.--% | - | |
| 8.06% | 0 M€ | -.--% | - | |
| 8.03% | 34 M€ | -6.56% | - | |
| 8.03% | 329 M€ | -10.97% | ||
| 7.89% | 6,059 M€ | -6.62% | ||
| 5.81% | 232 M€ | -9.17% | ||
| 5.23% | 2 M€ | -.--% | ||
| 5.08% | 199 M€ | -5.90% | ||
| 4.86% | 27 M€ | -6.48% | - | |
| 4.86% | 16 M€ | -.--% | - | |
| 4.86% | 132 M€ | -7.59% | - | |
| 4.80% | 12 M€ | -7.08% | - | |
| 4.80% | 50 M€ | -6.86% | - | |
| 4.80% | 1 M€ | -.--% | - | |
| 4.62% | 33 M€ | -1.36% | ||
| 4.53% | 3 M€ | -15.62% | ||
| 4.35% | 6 M€ | 0.00% | ||
| 4.10% | 8 M€ | 0.00% | - | |
| 4.07% | 169 M€ | +5.66% | - | |
| 3.92% | 331 M€ | +1.78% | - | |
| 3.80% | 6 M€ | 0.00% | - | |
| 3.67% | 16 M€ | 0.00% | - | |
| 3.55% | 1 M€ | -.--% | - | |
| 3.42% | 48 M€ | -4.26% | - | |
| 3.41% | 18 M€ | -8.42% | - | |
| 3.31% | 794 M€ | -1.68% | ||
| 3.31% | 69 M€ | -1.62% | - | |
| 3.23% | 1,043 M€ | -6.92% | ||
| 3.23% | 5 M€ | -11.77% | ||
| 3.22% | 132 M€ | +4.98% | - | |
| 3.01% | 89 M€ | -3.57% | - | |
| 2.91% | 5 M€ | -2.75% | - | |
| 2.90% | 775 M€ | -6.57% |
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
77.65USD
Average target price
90.39USD
Spread / Average Target
+16.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.54% | 96 755 M $ | |
| +59.64% | 525 B $ | |
| -10.34% | 381 B $ | |
| -6.75% | 262 B $ | |
| -11.26% | 253 B $ | |
| -17.52% | 221 B $ | |
| +2.14% | 202 B $ | |
| -9.09% | 200 B $ | |
| -43.58% | 163 B $ | |
| +3.74% | 146 B $ |
- Stock
- Equities
- Stock Gilead Sciences, Inc. - Nasdaq
- Funds and ETFs Gilead Sciences, Inc.
